HPB P59 Is the lymph node ratio a relevant prognostic score neo-adjuvant chemotherapy for pancreatic cancer?


 
 
 Lymph node ratio (LNR) is a strong prognostic marker in pancreatic cancer (PDAC). In recent years, use of neoadjuvant chemotherapy (NAT) has increased, where it is associated with a higher rate of N0 resections, compared with a surgery first approach. The prognostic accuracy of the LNR after NAT has not been assessed.
 
 
 
 Retrospective review of prospectively collected data from 2008–2020 of all patients undergoing pancreaticoduodenectomy (PD) for PDAC. Basic demographics, pathological and clinical outcomes were analysed using standard statistical tests. Cox regression and Kaplan-Meier analyses were performed.
 
 
 
 Retrospective review of prospectively collected data from 2008–2020 of all patients undergoing pancreaticoduodenectomy (PD) for PDAC. Basic demographics, pathological and clinical outcomes were analysed using standard statistical tests. Cox regression and Kaplan-Meier analyses were performed.
 
 
 
 NAT reduces the predictive accuracy of the LNR in resected pancreatic cancer; alternative prognostic models will require development.
